AKT1 and familial pancreatic carcinoma: Moreover, it was verified by in vitro and in vivo experiments that linderalactone (compound 53 in Table 1) inhibited the development of pancreatic cancer via negatively regulating the phosphatidylinositol 3 kinase (PI3K)/protein kinase B (AKT) signaling pathway (74).